DE69632476D1 - Behandlung von dilatierte kardiomyopathie durch entfernung von autoantikoerpern - Google Patents

Behandlung von dilatierte kardiomyopathie durch entfernung von autoantikoerpern

Info

Publication number
DE69632476D1
DE69632476D1 DE69632476T DE69632476T DE69632476D1 DE 69632476 D1 DE69632476 D1 DE 69632476D1 DE 69632476 T DE69632476 T DE 69632476T DE 69632476 T DE69632476 T DE 69632476T DE 69632476 D1 DE69632476 D1 DE 69632476D1
Authority
DE
Germany
Prior art keywords
patient
treatment
column
immunoapheresis
pressure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69632476T
Other languages
English (en)
Other versions
DE69632476T3 (de
DE69632476T2 (de
Inventor
Petra Reinke
Stefan Brehme
Gert Baumann
Robert Koll
Jutta Mueller-Derlich
Stephan Felix
Reiner Spaethe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Edwards Lifesciences Corp
Original Assignee
Edwards Lifesciences Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24232937&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69632476(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Edwards Lifesciences Corp filed Critical Edwards Lifesciences Corp
Application granted granted Critical
Publication of DE69632476D1 publication Critical patent/DE69632476D1/de
Publication of DE69632476T2 publication Critical patent/DE69632476T2/de
Publication of DE69632476T3 publication Critical patent/DE69632476T3/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 - B01D15/36
    • B01D15/3804—Affinity chromatography
    • B01D15/3809—Affinity chromatography of the antigen-antibody type, e.g. protein A, G, L chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/81—Drug, bio-affecting and body treating compositions involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, immunotolerance, or anergy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Neurology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • External Artificial Organs (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Developing Agents For Electrophotography (AREA)
  • Treatments Of Macromolecular Shaped Articles (AREA)
DE69632476.8T 1995-11-15 1996-11-15 Behandlung von dilatierte kardiomyopathie durch entfernung von autoantikoerpern Expired - Lifetime DE69632476T3 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US55926295A 1995-11-15 1995-11-15
US559262 1995-11-15
EP96941378.0A EP0862444B2 (de) 1995-11-15 1996-11-15 Behandlung von dilatierte kardiomyopathie durch entfernung von autoantikoerpern
PCT/US1996/018457 WO1997017980A1 (en) 1995-11-15 1996-11-15 Treatment of cardiomyopathy by removal of autoantibodies

Publications (3)

Publication Number Publication Date
DE69632476D1 true DE69632476D1 (de) 2004-06-17
DE69632476T2 DE69632476T2 (de) 2005-05-12
DE69632476T3 DE69632476T3 (de) 2014-05-22

Family

ID=24232937

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69632476.8T Expired - Lifetime DE69632476T3 (de) 1995-11-15 1996-11-15 Behandlung von dilatierte kardiomyopathie durch entfernung von autoantikoerpern

Country Status (7)

Country Link
US (1) US7022322B2 (de)
EP (1) EP0862444B2 (de)
JP (1) JP2002504831A (de)
AT (1) ATE266415T1 (de)
AU (1) AU731452B2 (de)
DE (1) DE69632476T3 (de)
WO (1) WO1997017980A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6620382B1 (en) 1998-05-22 2003-09-16 Biopheresis Technologies, Llc. Method and compositions for treatment of cancers
US8197430B1 (en) * 1998-05-22 2012-06-12 Biopheresis Technologies, Inc. Method and system to remove cytokine inhibitor in patients
US6406861B1 (en) * 1998-10-07 2002-06-18 Cell Genesys, Inc. Methods of enhancing effectiveness of therapeutic viral immunogenic agent administration
US6464976B1 (en) * 1999-09-07 2002-10-15 Canji, Inc. Methods and compositions for reducing immune response
US6379708B1 (en) * 1999-11-20 2002-04-30 Cytologic, Llc Method for enhancing immune responses in mammals
US8609436B2 (en) 2000-03-17 2013-12-17 Guy's & St Thomas' Hospital NHS Trust (“GST”) Method
US8088586B2 (en) * 2000-03-17 2012-01-03 Oxford Radcliffe Hospital Nhs Trust Method of producing a body fluid sample depleted of anti-MHC antibodies
JP4541490B2 (ja) * 2000-04-07 2010-09-08 株式会社カネカ 拡張型心筋症用吸着体
WO2003012396A2 (en) * 2001-08-01 2003-02-13 Chauhan Anil K Immune complexes
JP2008511340A (ja) * 2004-04-30 2008-04-17 バイオフェレシス テクノロジーズ， インコーポレイテッド 患者において可溶性ｔｎｆｒ１、可溶性ｔｎｆｒ２、および可溶性ｉｌ２を除去する方法およびシステム
US8034785B2 (en) 2004-10-28 2011-10-11 Kaneka Corporation Adsorbent adsorbing antibody against β1 adrenoreceptor
US20070065514A1 (en) * 2005-09-22 2007-03-22 Howell Mark D Method for enhancing immune responses in mammals
EP1832600A1 (de) * 2006-03-09 2007-09-12 Max-Delbrück-Centrum Für Molekulare Medizin Peptide gegen Autoantikörper verbunden mit Glaukom und deren Verwendung
DE102006042012A1 (de) * 2006-09-07 2008-03-27 Fresenius Medical Care Deutschland Gmbh Verfahren zur Unterstützung von Immuntherapien
US20080075690A1 (en) * 2006-09-22 2008-03-27 Mark Douglas Howell Method for enhancing immune responses in mammals
JPWO2008099855A1 (ja) * 2007-02-14 2010-05-27 旭化成クラレメディカル株式会社 自己抗体吸着材
US7601689B2 (en) * 2007-04-12 2009-10-13 Naidu Lp Angiogenin complexes (ANGex) and uses thereof
US8420330B2 (en) * 2011-07-15 2013-04-16 Myra A. Lipes Diagnosis and treatment of cardiac troponin 1 (cTn1) autoantibody-mediated heart disease
WO2009041037A1 (ja) * 2007-09-26 2009-04-02 Japan As Represented By The President Of National Cardiovascular Center 体内に存在する病因物質の低下剤
EP2110140A1 (de) * 2008-04-18 2009-10-21 Gert Baumann Behandlung von Thromboangiitis obliterans mittels Autoantikörperentfernung
KR20100041277A (ko) * 2008-10-13 2010-04-22 재단법인서울대학교산학협력재단 응집핵이 결합된 고분자 지지체
EP3110317B1 (de) 2014-02-25 2023-05-03 ICU Medical, Inc. Patientenüberwachungssystem mit gatekeeper-signal und entsprechendes verfahren
AU2016341195B2 (en) 2015-10-19 2019-03-14 Icu Medical, Inc. Hemodynamic monitoring system with detachable display unit
EP3607978A1 (de) * 2018-08-06 2020-02-12 Pentracor GmbH Vereinfachte regeneration von apheresesäulen
WO2022020569A1 (en) * 2020-07-22 2022-01-27 The Rockefeller University Type 1 ifn assays and methods of diagnosis for susceptibility to and treatment of viral disease and viral vaccines, including covid-19

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4223672A (en) * 1979-02-08 1980-09-23 Baxter Travenol Laboratories, Inc. Variable volume plasma treatment chamber for an apparatus for the extracorporeal treatment of disease
US4681870A (en) * 1985-01-11 1987-07-21 Imre Corporation Protein A-silica immunoadsorbent and process for its production
AU7958891A (en) * 1990-05-07 1991-11-27 Oklahoma Medical Research Foundation Nucleotide sequence encoding a 52 kda ro/ssa autoantigen
EP0585356A1 (de) * 1991-05-15 1994-03-09 Zymogenetics, Inc. Klonierung und expression des humanen glutamiksaeuredekarboylase-autoantigens aus dem inselorgan
US5295953A (en) * 1992-05-26 1994-03-22 Hemagen/Pfc Method and apparatus for extracorporeal separation of fluorochemicals from whole blood of a patient
WO1995031727A1 (en) * 1994-05-13 1995-11-23 Therasorb Medizinische Systeme Gmbh Sterile and pyrogen-free columns coupled to protein for binding and removal of substances from blood

Also Published As

Publication number Publication date
AU1054097A (en) 1997-06-05
ATE266415T1 (de) 2004-05-15
US20030125657A1 (en) 2003-07-03
DE69632476T3 (de) 2014-05-22
EP0862444B2 (de) 2014-04-09
US7022322B2 (en) 2006-04-04
WO1997017980A1 (en) 1997-05-22
DE69632476T2 (de) 2005-05-12
JP2002504831A (ja) 2002-02-12
EP0862444B1 (de) 2004-05-12
AU731452B2 (en) 2001-03-29
EP0862444A1 (de) 1998-09-09

Similar Documents

Publication Publication Date Title
DE69632476D1 (de) Behandlung von dilatierte kardiomyopathie durch entfernung von autoantikoerpern
LTC1504035I2 (lt) Antikūnai, specifiški žmogaus cd22, ir jų terapinis bei diagnostinis panaudojimas
ATE482234T1 (de) Antikörper gegen kdr, deren herstellung und verwendungen
EA200001169A1 (ru) Специфично связывающиеся молекулы для сцинтиграфии, содержащие их конъюгаты и терапевтический способ лечения ангиогенеза
ATE347910T1 (de) Zusammensetzungen zur behandlung von ischamischem gewebe
MY136603A (en) Biological products
DE69535133D1 (de) Humanisierte antikörper gegen das leukozytenadhäsionsmolekül vla-4
FR2703693B1 (fr) Procédé rapide de détermination d'une séquence d'ADN et application au séquençage et au diagnostic.
ATE364699T1 (de) Humanisierte antikörper gegen humanes gp39, zusammensetzungen die diese enthalten und deren therapeutische verwendungen
DE69034261D1 (de) Antikörper gegen VLA-4
DE69334158D1 (de) Monoklonale Antikörper gegen den Interferonrezeptor, mit neutralisierender Aktivität gegen Typ I-Interferon
DK43890D0 (da) Nucleinsyre, vektorer og celler indeholdende den, derudfra fremstillede produkter og disses anvendelse
DE69129460D1 (de) Verwendung von Anti-ICAM Antikörpern zur Herstellung eines Präparats für die BEHANDLUNG VON ENDOTOXINSCHOCK
DK0948536T3 (da) G-protein-koblet receptor med et forstörret extracellulært domæne
BR9603826A (pt) Processo para recuperar imunoglobulina de frações produzidas durante o fracionamento de plasma sanguíneo humano
ATE191502T1 (de) Corticotropinauslösefaktor-bindendes protein
DE59508509D1 (de) Dna-expressionsvektoren zur verwendung in der gentherapeutischen behandlung von gefässerkrankungen
CA2236598A1 (en) Treatment of cardiomyopathy by removal of autoantibodies
ATE317021T1 (de) Antisense modulierung von lfa-3
DE3850933D1 (de) Anticoagulatorisches Protein PP4-X, seine Herstellung und Verwendung.
DE69232140D1 (de) Die herstellung von menschlichen, monoklonalen antikörpern, die gegen das oberflächenantigen von hepatitis b aktiv sind
DE59207362D1 (de) Monoklonale Antikörper gegen den Plasmin-Antiplasmin Komplex, Verfahren zu ihrer Herstellung sowie ihre Verwendung
EP0338436A3 (de) Monoklonale Antikörper gegen das Neuropeptid Y, Verfahren zu ihrer Herstellung sowie ihre Verwendung
ATE235260T1 (de) Verfahren zum herstellen von nebenwirkungsfreien konstrastmitteln bei ultrafiltration
DE69010897T2 (de) Verwendung von monoklonalen Antikörpern gegen B2-Mikroglobulin.